A web-blog (formerly known as Stu's Views and MS News), now published by MS Views and News, a patient advocacy organization. The information on this blog helps to Empower those affected by Multiple Sclerosis globally, with education, information, news and community resources.
~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Friday, December 20, 2013
Genzyme’s Lemtrada™ Approved in Australia for Treatment of Multiple Sclerosis
Dec 19, 2013
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that the Australian Therapeutic Goods Administration (TGA) has approved Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis for patients with active disease defined by clinical or imaging features to slow the accumulation of physical disability and reduce the frequency of clinical relapses.
“Multiple Sclerosis is a highly complex and often devastating disease that can lead to significant disability in patients, despite availability of standard therapies,” said Associate Professor John King, Senior Neurologist, Royal Melbourne Hospital. “Lemtrada represents a significant advance in the way physicians and patients can think about treating multiple sclerosis. The efficacy data supporting Lemtrada highlight its strong potential to impact disease progression in patients with relapsing forms of MS.”
Lemtrada is supported by a comprehensive and extensive clinical development program that involved nearly 1,500 patients and 5,400 patient-years of follow-up. Approval in Australia follows the recent approval of Lemtrada in Canada and the European Union. Marketing applications for Lemtrada are also under review in other countries.
More than 2.3 million people worldwide have been diagnosed with MS, including approximately 20,000 people in Australia.
Lemtrada 12 mg has a novel dosing and administration schedule of two annual treatment courses. The first treatment course of Lemtrada is administered via intravenous infusion on five consecutive days, and the second course is administered on three consecutive days, 12 months later.
“The approval of Lemtrada in Australia reinforces the significance of this treatment and is an important milestone in Genzyme’s commitment to bring this potentially transformative therapy to patients globally,” said David Meeker, President and CEO, Genzyme. “We’re very pleased with the TGA’s approval and look forward to working with the reimbursement authorities to make Lemtrada available to patients in Australia.”